MX2024003968A - Profarmacos de axitinib. - Google Patents
Profarmacos de axitinib.Info
- Publication number
- MX2024003968A MX2024003968A MX2024003968A MX2024003968A MX2024003968A MX 2024003968 A MX2024003968 A MX 2024003968A MX 2024003968 A MX2024003968 A MX 2024003968A MX 2024003968 A MX2024003968 A MX 2024003968A MX 2024003968 A MX2024003968 A MX 2024003968A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- oco
- och
- cooh
- Prior art date
Links
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 title 1
- 229960003005 axitinib Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255998P | 2021-10-15 | 2021-10-15 | |
| PCT/US2022/046750 WO2023064578A1 (en) | 2021-10-15 | 2022-10-14 | Prodrugs of axitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003968A true MX2024003968A (es) | 2024-04-29 |
Family
ID=85987895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003968A MX2024003968A (es) | 2021-10-15 | 2022-10-14 | Profarmacos de axitinib. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250092013A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4416132A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024537839A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118119599A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022362310A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232086A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003968A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023064578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119947722A (zh) * | 2022-10-14 | 2025-05-06 | 视尔普斯眼科公司 | 前药、制剂及其方法 |
| JP2026520094A (ja) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス，インコーポレイテッド | アキシチニブ多形ｉｖを含む眼科インプラント |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5721949B2 (ja) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| WO2016183296A1 (en) * | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
| TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| CN106336397A (zh) * | 2015-07-07 | 2017-01-18 | 郭明山 | 一种作为治疗眼科疾病的新化合物 |
| WO2021035360A1 (en) * | 2019-08-30 | 2021-03-04 | Risen (Suzhou) Pharma Tech Co., Ltd. | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
| US12637441B2 (en) * | 2019-08-30 | 2026-05-26 | Risen (Suzhou) Pharma Tech Co., Ltd. | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
| CN112442010B (zh) * | 2019-08-30 | 2023-10-03 | 润佳（苏州）医药科技有限公司 | 一类前药化合物及其在治疗癌症方面的应用 |
| CA3171563A1 (en) * | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
-
2022
- 2022-10-14 CA CA3232086A patent/CA3232086A1/en active Pending
- 2022-10-14 WO PCT/US2022/046750 patent/WO2023064578A1/en not_active Ceased
- 2022-10-14 US US18/706,306 patent/US20250092013A1/en active Pending
- 2022-10-14 CN CN202280066784.0A patent/CN118119599A/zh active Pending
- 2022-10-14 AU AU2022362310A patent/AU2022362310A1/en active Pending
- 2022-10-14 MX MX2024003968A patent/MX2024003968A/es unknown
- 2022-10-14 EP EP22881846.4A patent/EP4416132A4/en active Pending
- 2022-10-14 JP JP2024519989A patent/JP2024537839A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4416132A4 (en) | 2025-09-03 |
| US20250092013A1 (en) | 2025-03-20 |
| EP4416132A1 (en) | 2024-08-21 |
| CA3232086A1 (en) | 2023-04-20 |
| WO2023064578A1 (en) | 2023-04-20 |
| CN118119599A (zh) | 2024-05-31 |
| JP2024537839A (ja) | 2024-10-16 |
| AU2022362310A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MY117290A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | |
| CY1110468T1 (el) | Χρηση αναστολεων γλυκοσιδασης για μια θεραπεια της κυστικης ινωσεως | |
| MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
| PT1280809E (pt) | Derivados antitumorais de ecteinascidina | |
| ATE74134T1 (de) | Rapamycin-vorlaeufer. | |
| FI924227A0 (fi) | Nya alkoxisubstituerade taxaner och farmaceutiska kompositioner innehaollande dessa. | |
| BRPI0211844B8 (pt) | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica | |
| CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| EA200000400A1 (ru) | Галогензамещенные тетрациклические производные тетрагидрофурана | |
| BRPI0409105A (pt) | análogos de quinobenzoxazina substituìdos | |
| MX2025003792A (es) | Profarmacos, formulaciones y metodos de estos | |
| NO20052074L (no) | Substituerte benzoksazinoner og anvendelser derav. | |
| CL2024001298A1 (es) | Compuestos de cd73 | |
| WO2001098248A3 (en) | Hiv integrase inhibitors | |
| CL2023002908A1 (es) | Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3 | |
| ATE374750T1 (de) | Serotoninwiederaufnahme-inhibitoren | |
| DK1694641T3 (da) | Prostaglandinsyntese | |
| ATE447949T1 (de) | Vakuolar-typ (h+)-atpase-hemmende verbindungen, zusammensetzungen und deren verwendungen | |
| MX2024005101A (es) | Profármacos de l-bhdu y métodos para tratar infecciones virales. | |
| ATE247108T1 (de) | Antifungale tetrahydrofurane | |
| AR127559A1 (es) | Compuestos, composiciones y métodos | |
| SE9701245D0 (sv) | Antivirals |